title: Increased expression of the antiapoptotic protein MCL1 in canine mast cell tumors.
abstract: Myeloid cell leukemia sequence 1 (MCL1) is a potent antiapoptotic protein that plays a critical role in cell survival and drug resistance in various cancers. However, to the best of our knowledge, the role of MCL1 in mast cell tumors (MCTs) has not been investigated in dogs. Here, we detected increased MCL1 expression in MCT cell lines, regardless of the presence of a c-kit mutation. MCL1 expression increased when the cells were exposed to specific inhibitors of mitogen-activated protein kinase or Janus kinase-signaling pathways, thus protecting the cells from apoptosis, but not when KIT or phosphatidylinositol-3 kinase signaling cascades were inhibited. These results indicate that MCL1 expression may contribute to MCT survival and confer drug resistance.
authors: Cooperative Major in Advanced Health Science, Graduate School of Bio-Applications and System Engineering, Tokyo University of Agriculture and Technology, Saiwai-cho, Fuchu, Tokyo 183-8509, Japan.
authors: Yosuke
authors: Y
authors: Amagai
authors: Akane
authors: A
authors: Tanaka
authors: Akira
authors: A
authors: Matsuda
authors: Kumiko
authors: K
authors: Oida
authors: Kyungsook
authors: K
authors: Jung
authors: Sho
authors: S
authors: Nishikawa
authors: Hyosun
authors: H
authors: Jang
authors: Saori
authors: S
authors: Ishizaka
authors: Hiroshi
authors: H
authors: Matsuda
mesh_terms: D000818:Animals; D001549:Benzamides / Q000494:pharmacology; D002867:Chromones / Q000494:pharmacology; D004283:Dog Diseases / Q000378:metabolism*; D004285:Dogs; D004591:Electrophoresis, Polyacrylamide Gel / Q000662:veterinary; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors; D005419:Flavonoids / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects* / Q000502:physiology; D000068877:Imatinib Mesylate; D053612:Janus Kinases / Q000037:antagonists & inhibitors; D034801:Mastocytoma / Q000378:metabolism / Q000662:veterinary*; D009025:Morpholines / Q000494:pharmacology; D064549:Myeloid Cell Leukemia Sequence 1 Protein / Q000378:metabolism*; D010879:Piperazines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D020123:Sirolimus / Q000494:pharmacology; D020032:Tyrphostins / Q000494:pharmacology
chemical_list: D001549:Benzamides; D002867:Chromones; D005419:Flavonoids; D009025:Morpholines; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D010879:Piperazines; D011743:Pyrimidines; D020032:Tyrphostins; C095512:alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D000068877:Imatinib Mesylate; D053612:Janus Kinases; D048049:Extracellular Signal-Regulated MAP Kinases; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; D020123:Sirolimus